New Alzheimer's drug 'Aducanumab' from the American pharmaceutical company Biogen, not only stops the advance of Alzheimer's - it reverses the damage done. The pharmaceutical company in a press release said that the drug performed well in initial trails and they are planning for a second phase trail.
"Treatment with aducanumab produced a dose-and-time-dependent reduction of amyloid plaque in the brain. Amyloid plaque is believed to play a key role in the development of the symptoms of AD," the press release said.
The company acknowledged that their initial studies did not have a large test group. Hence, they are aiming for a new and more ambitious phase of studies, expected to get underway by the end of 2015. The most significant study they've conducted on the drug to date had 166 patients with early to mild
Spokesperson Kate NIazo-Sai said they expect to gain approval to market the drug to patients of Alzheimer's and other dementia soon.
"A lot of potential Alzheimer's drugs never quite make it. But the results we have seen in a relatively small patient sample are very hopeful. If this was replicated in a further trial, then it could change the landscape for treatment of Alzheimer's," Niazo-Sai said.